Cargando…

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

BACKGROUND: Twelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab. In this tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M., Earl, Helena M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887251/ https://www.ncbi.nlm.nih.gov/pubmed/29621991 http://dx.doi.org/10.1186/s12885-018-4307-8

Ejemplares similares

Trastuzumab-associated cardiac events in the Persephone trial
por: Earl, Helena M, et al.
Publicado: (2016)

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
por: Earl, Helena M, et al.
Publicado: (2019)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Perséphone : mélodrame en trois tableaux
por: Stravinsky, Igor, 1882-1971
Publicado: (1950)

Optimising patient recall of adverse events over prolonged time periods
por: Hiller, Louise, et al.
Publicado: (2011)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators
por: Scheer, Justin M., et al.
Publicado: (2012)

The Circulating Protease Persephone Is an Immune Sensor for Microbial Proteolytic Activities Upstream of the Drosophila Toll Pathway
por: Issa, Najwa, et al.
Publicado: (2018)

The complete and closed genome of the facultative generalist Candidatus Endoriftia persephone from deep‐sea hydrothermal vents
por: De Oliveira, André Luiz, et al.
Publicado: (2022)

Damage sensing mediated by serine proteases Hayan and Persephone for Toll pathway activation in apoptosis-deficient flies
por: Nakano, Shotaro, et al.
Publicado: (2023)

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
por: Lin, Nancy, et al.
Publicado: (2020)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
por: Witzel, Isabell, et al.
Publicado: (2014)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
por: Alba, E, et al.
Publicado: (2014)

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2023)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
por: Assenat, Eric, et al.
Publicado: (2015)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
por: Swain, S. M., et al.
Publicado: (2014)

Loss of Slc4a1b Chloride/Bicarbonate Exchanger Function Protects Mechanosensory Hair Cells from Aminoglycoside Damage in the Zebrafish Mutant persephone
por: Hailey, Dale W., et al.
Publicado: (2012)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Some Endpoint Results for β-Generalized Weak Contractive Multifunctions
por: Alikhani, H., et al.
Publicado: (2013)

Polio: abandoning eradication would result in rapid resurgence of an ancient scourge
por: Sutter, Roland Walter, et al.
Publicado: (2019)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial
por: Geurts, V.C.M., et al.
Publicado: (2023)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

Does prior exercise affect oral glucose tolerance test results?
por: Titchenal, C Alan, et al.
Publicado: (2008)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
por: Bundred, Nigel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9lotqnpenlgt2i3rcapa7vp0fv